Why Birkenstock Flopped in Its IPO Today
Shares of the German sandal-maker fell on opening day.
Mindfully Curated
Shares of the German sandal-maker fell on opening day.
Shares of the German sandal-maker fell on opening day.
ChargePoint’s latest move is yet another reflection of the company’s ongoing struggles.
ChargePoint’s latest move is yet another reflection of the company’s ongoing struggles.
The supply chain software specialist delivered an underwhelming quarter, lowered its full-year outlook, and replaced its CEO. Here’s what investors need to know.
The supply chain software specialist delivered an underwhelming quarter, lowered its full-year outlook, and replaced its CEO. Here’s what investors need to know.
The company’s stock climbed after a proposal by a private equity firm to buy up available stock.
The company’s stock climbed after a proposal by a private equity firm to buy up available stock.
Uncover two hidden gems in tech, ready to thrive amid the economic chill of October 2023.
Uncover two hidden gems in tech, ready to thrive amid the economic chill of October 2023.
Star witness and former girlfriend of Sam Bankman-Fried says he directed the crimes. So far, the Sam Bankman-Fried trial can be summed…
Star witness and former girlfriend of Sam Bankman-Fried says he directed the crimes. So far, the Sam Bankman-Fried trial can be summed…
It is absolutely reasonable right now to be flummoxed by the economy. A brief assessment of the terrain: Interest rates on 30-year mortgages just…
It is absolutely reasonable right now to be flummoxed by the economy. A brief assessment of the terrain: Interest rates on 30-year mortgages just…
Novo Nordisk indicated one of its diabetes drugs could also be used to treat kidney disease. Here’s what investors need to know.
Novo Nordisk indicated one of its diabetes drugs could also be used to treat kidney disease. Here’s what investors need to know.
VOXX earnings call for the period ending September 30, 2023.
VOXX earnings call for the period ending September 30, 2023.
Positive trial news for a kidney failure drug could cut into business for dialysis therapies companies such as Fresenius.
Positive trial news for a kidney failure drug could cut into business for dialysis therapies companies such as Fresenius.